To make your have a beauty and healthy life, and dream about the perfect one
contact usTo make your have a beauty and healthy life, and dream about the perfect one
contact usNo products at this time.
No products at this time.
No products at this time.
It is a drug used for certain breast, lung and other cancers. Gefitinib is the first selective inhibitor of epidermal growth factor receptor’s (EGFR) tyrosine kinase domain. Thus Gefitinib is an EGFR inhibitor. The target protein (EGFR) is a family of receptors which includes Her 1(erb-B1), Her 2(erb-B2), and Her 3(erb-B3). EGFR is over expressed in the...
IMACY-100mgTyrosine kinase inhibitors (TKIs) have been approved for cancer treatment and numerous are under investigation. These drugs are rationally designed to target specific tyrosine kinases that are mutated and/or over-expressed in cancer tissues. Ninety-five percent of all chronic myelogenous leukemia (CML) was suggested to be the result of the...
No products at this time.
It is a drug used for certain breast, lung and other cancers. Gefitinib is the first selective inhibitor of epidermal growth factor receptor’s (EGFR) tyrosine kinase domain. Thus Gefitinib is an EGFR inhibitor. The target protein (EGFR) is a family of receptors which includes Her 1(erb-B1), Her 2(erb-B2), and Her 3(erb-B3). EGFR is over expressed in the...
IMACY-100mgTyrosine kinase inhibitors (TKIs) have been approved for cancer treatment and numerous are under investigation. These drugs are rationally designed to target specific tyrosine kinases that are mutated and/or over-expressed in cancer tissues. Ninety-five percent of all chronic myelogenous leukemia (CML) was suggested to be the result of the...


No products at this time.
No products at this time.
No products at this time.
It is a drug used for certain breast, lung and other cancers. Gefitinib is the first selective inhibitor of epidermal growth factor receptor’s (EGFR) tyrosine kinase domain. Thus Gefitinib is an EGFR inhibitor. The target protein (EGFR) is a family of receptors which includes Her 1(erb-B1), Her 2(erb-B2), and Her 3(erb-B3). EGFR is over expressed in the...
IMACY-100mgTyrosine kinase inhibitors (TKIs) have been approved for cancer treatment and numerous are under investigation. These drugs are rationally designed to target specific tyrosine kinases that are mutated and/or over-expressed in cancer tissues. Ninety-five percent of all chronic myelogenous leukemia (CML) was suggested to be the result of the...
No products at this time.
It is a drug used for certain breast, lung and other cancers. Gefitinib is the first selective inhibitor of epidermal growth factor receptor’s (EGFR) tyrosine kinase domain. Thus Gefitinib is an EGFR inhibitor. The target protein (EGFR) is a family of receptors which includes Her 1(erb-B1), Her 2(erb-B2), and Her 3(erb-B3). EGFR is over expressed in the...
IMACY-100mgTyrosine kinase inhibitors (TKIs) have been approved for cancer treatment and numerous are under investigation. These drugs are rationally designed to target specific tyrosine kinases that are mutated and/or over-expressed in cancer tissues. Ninety-five percent of all chronic myelogenous leukemia (CML) was suggested to be the result of the...
Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exerci tation ullamcorper suscipit
contact usSuspendisse posuere, diam in bibendum lobortis, turpis ipsum aliquam risus, sit amet dictum ligula lorem non nisl Urna pretium elit mauris cursus Curabitur...
Turpis at eleifend leo mi elit Aenean porta ac sed faucibus. Nunc urna Morbi fringilla vitae orci convallis condimentum auctor sit dui. Urna pretium elit...
Sed mauris Pellentesque elit Aliquam at lacus interdum nascetur elit ipsum. Enim ipsum hendrerit Suspendisse turpis laoreet fames tempus ligula pede ac. Et...
Mi vitae magnis Fusce laoreet nibh felis porttitor laoreet Vestibulum faucibus. At Nulla id tincidunt ut sed semper vel Lorem condimentum ornare.
Mi vitae magnis Fusce laoreet nibh felis porttitor laoreet Vestibulum faucibus. At Nulla id tincidunt ut sed semper vel Lorem condimentum ornare.
Donec tellus Nulla lorem Nullam elit id ut elit feugiat lacus. Congue eget dapibus congue tincidunt senectus nibh risus Phasellus tristique justo. Justo...